David B. Zhen, MD

Samuel Cytryn, MD, and David B. Zhen, MD, discuss how immunotherapy plus chemotherapy has improved the durability of outcomes in advanced GI cancers.

Samuel Cytryn, MD, and David B. Zhen, MD, on factors for selecting nivolumab plus chemotherapy or ipilimumab in esophageal squamous cell carcinoma.

Samuel Cytryn, MD, and David B. Zhen, MD, on long-term data for nivolumab plus chemotherapy or ipilimumab in advanced esophageal squamous cell carcinoma.

Samuel Cytryn, MD, and David B. Zhen, MD, discuss findings from a Q-TWiST analysis of the CheckMate 649 trial in advanced gastric/GEJ cancer.

Samuel Cytryn, MD, and David B. Zhen, MD, on 4-year data from CheckMate 649 for nivolumab plus chemotherapy in first-line advanced gastric/GEJ cancer.

Samuel Cytryn, MD, and David B. Zhen, MD, discuss how immunotherapy has affected the treatment paradigm for upper gastrointestinal cancers.

David Zhen, MD, discusses future research efforts in poorly differentiated small cell neuroendocrine carcinomas.

David Zhen, MD, discusses the need for novel therapies in poorly differentiated small-cell-type neuroendocrine tumors.

David Zhen, MD, discusses advancements in the treatment of patients with gastroenteropancreatic neuroendocrine tumors.